Company: PMVP
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001140361-25-015610
Chunk: 42

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 42
---
 December 31, 2024. In addition, with regard to the Company’s trading in its own securities, it is our policy to comply with the federal securities laws and the applicable exchange listing requirements. Policy Prohibiting Hedging or Pledging of Securities Under our insider trading policy, our employees, including our executive officers, and the members of our board of directors are prohibited from, directly or indirectly, among other things, (1) engaging in short sales, (2) trading in publicly-traded options, such as puts and calls, and other derivative securities with respect to our securities (other than stock options, restricted stock units and other compensatory awards issued to such individuals by us), (3) purchasing financial instruments (including prepaid variable forward contracts, equity swaps, collars and exchange funds), or otherwise engaging in transactions that hedge or offset, or are designed to hedge or offset, any decrease in the market value of equity securities granted to them by us as part of their compensation or held, directly or indirectly, by them. In addition, our executive officers and the members of our board of directors are prohibited from, directly or indirectly, pledging any of our securities as collateral for any loans and holding our securities in a margin account. Policies and Practices for Granting Certain Equity Awards Our board of directors and the compensation committee do not take material nonpublic information into account when determining the timing and terms of any stock option grant. We have not timed the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation.We have not adopted a formal policy related to timing of awards of stock options in relation to the disclosure of material nonpublic information. The following table presents information regarding stock options issued to our named executive officers in 2024 during any period beginning four business days before the filing of a periodic report or current report disclosing material nonpublic information and ending one business day after the filing or furnishing of such report with the SEC.The following stock option grants were made on the same date that that we filed a Current Report on Form 8-K on January 18, 2024 with the SEC related to Item 2.05 announcing our restructuring plan involving the reduction of our workforce. Such Current Report on Form 8-K is not incorporated herein by reference.

| Name                     |     | Grant date |     |      Number of 
     securities 
 underlying the 
          award |     |     Exercise 
 price of the 
        award 
       ($/Sh) |     |    Grant date 
 fair value of